Literature DB >> 12166654

Relation between angiotensin-converting enzyme II genotype and atrial fibrillation in Japanese patients with hypertrophic cardiomyopathy.

Akiyoshi Ogimoto1, Mareomi Hamada, Jun Nakura, Tetsuro Miki, Kunio Hiwada.   

Abstract

Atrial fibrillation (AF) occurs in about 20% of patients with hypertrophic cardiomyopathy (HCM). HCM patients with AF have an increased risk for clinical decline and thromboembolism. In addition, AF is known to be associated with the atrial renin-angiotensin system (RAS). However, the relation between AF and the RAS in HCM has not been investigated. We genotyped the insertion/ deletion (I/D) polymorphism of the angiotensin-converting enzyme (ACE) gene in 138 HCM patients (26 with AF, 112 with sinus rhythm). Distribution of the ACE genotypes (DD, ID, and II) among the total HCM patients was 15%, 46%, and 38%. AF was documented in 3 patients with the DD genotype, 7 with the ID genotype, and 16 with the II genotype (P < 0.03 vs. sinus rhythm group). The odds of AF were 3.2-fold greater in patients with the II genotype than in those with the other genotypes (P = 0.009, 95% confidence interval = 1.3-7.8). Kaplan-Meier curves examining the time to the first documented AF event showed a significant difference between genotypes during the follow-up period (mean 116 months, P < 0.05). These findings suggest that the II genotype of the ACE gene is a significant risk factor for AF in patients with HCM.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12166654     DOI: 10.1007/s100380200021

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  15 in total

1.  Prognostic impact of atrial fibrillation in hypertrophic cardiomyopathy: a systematic review.

Authors:  Patricia Alphonse; Sohaib Virk; Jhonna Collins; Timothy Campbell; Stuart P Thomas; Christopher Semsarian; Saurabh Kumar
Journal:  Clin Res Cardiol       Date:  2020-09-03       Impact factor: 5.460

2.  Atrial Fibrillation and Anticoagulation in Hypertrophic Cardiomyopathy.

Authors:  C Fielder Camm; A John Camm
Journal:  Arrhythm Electrophysiol Rev       Date:  2017-06

Review 3.  Ischaemic events in hypertrophic cardiomyopathy patients with and without atrial fibrillation: a systematic review and meta-analysis.

Authors:  Tiffany T S Ye; Qi Zhuang Siah; Benjamin Y Q Tan; Jamie S Y Ho; Nicholas L X Syn; Yao Hao Teo; Yao Neng Teo; James W Yip; Tiong-Cheng Yeo; Weiqin Lin; Raymond C C Wong; Ping Chai; Bernard Chan; Vijay Kumar Sharma; Leonard L L Yeo; Ching-Hui Sia
Journal:  J Thromb Thrombolysis       Date:  2022-10-03       Impact factor: 5.221

4.  The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy: a pilot, randomized study.

Authors:  Martin Penicka; Pavel Gregor; Roman Kerekes; Dan Marek; Karol Curila; Jiri Krupicka
Journal:  J Mol Diagn       Date:  2008-12-12       Impact factor: 5.568

Review 5.  The role of the renin-angiotensin system in atrial fibrillation and the therapeutic effects of ACE-Is and ARBS.

Authors:  Giuseppina Novo; Daniela Guttilla; Giovanni Fazio; Debbie Cooper; Salvatore Novo
Journal:  Br J Clin Pharmacol       Date:  2008-09       Impact factor: 4.335

Review 6.  Non-antiarrhythmic medications for atrial fibrillation: from bench to clinical practice.

Authors:  Maya Guglin; Marcos Garcia; Michael J Yarnoz; Anne B Curtis
Journal:  J Interv Card Electrophysiol       Date:  2008-03-04       Impact factor: 1.900

Review 7.  The influence of Angiotensin converting enzyme and angiotensinogen gene polymorphisms on hypertrophic cardiomyopathy.

Authors:  Rong Luo; Xiaoping Li; Yuequn Wang; Yongqing Li; Yun Deng; Yongqi Wan; Zhigang Jiang; Wei Hua; Xiushan Wu
Journal:  PLoS One       Date:  2013-10-25       Impact factor: 3.240

Review 8.  Genetic polymorphism of angiotensin-converting enzyme and hypertrophic cardiomyopathy risk: A systematic review and meta-analysis.

Authors:  Ye Yuan; Lin Meng; Yan Zhou; Na Lu
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

9.  Machine Learning Methods for Identifying Atrial Fibrillation Cases and Their Predictors in Patients With Hypertrophic Cardiomyopathy: The HCM-AF-Risk Model.

Authors:  Moumita Bhattacharya; Dai-Yin Lu; Ioannis Ventoulis; Gabriela V Greenland; Hulya Yalcin; Yufan Guan; Joseph E Marine; Jeffrey E Olgin; Stefan L Zimmerman; Theodore P Abraham; M Roselle Abraham; Hagit Shatkay
Journal:  CJC Open       Date:  2021-02-02

10.  Impact of angiotensin I converting enzyme insertion/deletion polymorphisms on dilated cardiomyopathy and hypertrophic cardiomyopathy risk.

Authors:  Jianmin Yang; Yunhan Zhao; Panpan Hao; Xiao Meng; Mei Dong; Ying Wang; Yun Zhang; Cheng Zhang
Journal:  PLoS One       Date:  2013-05-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.